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Abstract 
Purpose: Cyclophosphamide (CY) is a bifunctional alkylating agent long associated 
with immune activation. Continuous uninterrupted low (so-called metronomic) doses of 
CY can lead to enhanced immunity against a variety of antigens possibly by targeting 
regulatory T cells (T reg) and/or tumour angiogenesis. In this study we tested the 
observations from animal models and evaluated the safety and efficacy of continuous 
low dose oral CY in patients with HRPC. 
Materials and Methods: Eighty patients were recruited over a 2 year period and fifty 
eight received at least 2 cycles (8 weeks) of 50mg/m2 oral CY to be included in the 
safety and intention-to-treat analysis.  
Results: Metronomic CY was safe and well tolerated, and although lymphopaenia (up 
to grade 3) was observed in a third of all patients, there were no clinical complications. 
The response rate was 34.5% inclusive of objective and PSA (absolute reduction and 
reduction in PSA velocity). The median duration of response was 7.5 months (range 3-
18 months). 
Conclusions: Oral CY can be used on a metronomic basis safely in men with HRPC. 
The efficacy, low toxicity, low cost and ease of administration of CY justifies further 
studies in prostate cancer in combination with other agents. 
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Introduction 
Despite recent progress in the management of early and localised prostate cancer (PC), a 
substantial number of patients still develop hormone resistant (HRPC) and metastatic 
disease that can significantly impact on symptoms, quality of life and longevity1. There 
has been considerable interest in exploiting the immunostimulatory and antiangiogenic 
potential of drugs previously thought to be beneficial solely in terms of their 
cytotoxicity2.  Cyclophosphamide (CY) is a bifunctional alkylating agent which has 
been used to treat a very large range of malignancies and has also been long associated 
with immune activation3, and more recently with anti-angiogenesis. Low doses of CY 
can lead to enhanced immune responses against a variety of antigens.  In murine models, 
low dose CY decreases numbers of suppressor or regulatory T cells (T reg) and directly 
inhibits the suppressive capability of CD4+25+ T reg cells by enhancing apoptosis and 
decreasing homeostatic proliferation. Higher doses of CY are associated with 
cytotoxicity and immunosuppression, whereas continuous low dose scheduling may be 
immunostimulatory and/or antiangiogenic4. Metronomic dosing involves the chronic 
administration of comparatively low doses of CY at close, regular intervals, with no 
prolonged drug-free interruptions5. This approach is not necessarily designed with the 
intention of substantially increasing cumulative drug-dose over time; as such it 
minimizes host toxic side effects and the need for supportive care treatment. 
Metronomic dosing of agents such as CY or trofosfamide has shown surprisingly potent 
and durable antitumour effects in a number of models, including transplantable human 
lymphoma6 and human prostate carcinoma7.  
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In this study we have evaluated the safety and efficacy of continuous low dose oral 
cyclophophamide in patients with HRPC, both in view of its potential as a cost effective 
single agent to palliate HRPC but also possibly as a synergistic agent with cancer 
vaccines or other antiangiogenic agents. 
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Materials and methods 
 
Eligibility Criteria 
Men with histologically confirmed prostate cancer, who failed optimal first line 
androgen deprivation therapy with leutenizing hormone releasing hormone (LHRH) 
agonist drugs, total androgen blockade therapy or orchidectomy were eligible for the 
trial. Patients were required to have progressive disease as indicated by 2 consecutive 
rises in Prostate Specific Antigen (PSA), separated by at least four weeks, from a 
minimum level of 2ng/ml;, WHO performance status of 0-2 and a life expectancy of at 
least six months. Biochemical trial entry parameters included castrate levels of serum 
testosterone (<50ng/ml), adequate bone marrow function, as defined by white blood 
count of more than 3500/mm3, haemoglobin of more than 10g/dl, platelet count of at 
least 100000/ mm3; adequate renal function with serum creatinine of less than 2.0mg/dl 
and adequate hepatic function defined as less than 2 times upper limit of normal value 
for aspartate transaminase and alanine transaminase. Patients continued their LHRH 
agonist and/or antiandrogen therapy to avoid altered PSA kinetics associated with 
androgen withdrawal. All other treatments were discontinued.  Patients with visceral 
and brain metastases were excluded. All patients provided written informed consent. 
The study was approved by St Georges Hospital Local Research Ethics Committee. 
 
Trial design 
This was a single centre open label phase II study for patients with HRPC. Patients with 
hormone resistant rather than hormone refractory disease were selected on the basis that 
the addition of casodex withdrawal as a treatment does not alter the natural history of 
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the disease overall. Patients received oral cyclophosphamide 50mg/m2 continuously in 
4 weekly cycles without breaks, for a total of 12 cycles. Further treatment was allowed 
if only grade 1 or 2 toxicity had occurred. Adverse events were graded according to 
NCI Common Toxicity Criteria (CTC) version II. All patients underwent assessment of 
tumour status at baseline, six months and one year or at the time of withdrawal, using 
computed tomography (CT) and technicium-99 bone scan. Clinical examination, PSA 
monitoring, biochemical and haematological profiles were performed in all patients at 
the beginning of the study and at each 4 weekly visit. Patients were withdrawn from the 
study whenever any of the following occurred: PSA increase of 25% over baseline (or 
nadir if responding initially) after a minimum of 3 cycles and corroborated by a repeat 
PSA test within 2 weeks, disease progression (defined by Response Evaluation Criteria 
In Solid Tumours (RECIST) criteria), worsening of PC-related symptoms; patient 
initiated withdrawal for any reason; development of intercurrent illness requiring 
treatment with corticosteroids; development of any severe (> grade 3) toxicity or lack 
of compliance with the protocol. Objective responses were defined according to 
RECIST criteria. 
 
PSA Velocity 
PSAV was calculated for each patient pre-treatment and post-treatment, by fitting a 
regression model to the log of the PSA values. The model used was ln(PSA)/t, where t 
is the time between enrolment on the trial and the date of the PSA sample. PSA 
doubling time was calculated for each patient as ln(2)/PSA Velocity. 
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Study objectives and assessment of response. 
The primary endpoint of this study was PSA response (50% fall in PSA levels sustained 
for at least 4 weeks) as defined by PSA working group criteria. Secondary endpoints 
included proportion of evaluable patients who showed complete or partial objective 
radiological response to treatment, a fall in absolute PSA or a fall in PSA velocity, 
duration of any responses and the safety and tolerability of the continuous dosing. 
Measurement of serum markers of angiogenesis and enumeration and functional 
analysis of peripheral blood Treg was completed in a subset of patients. The study was a 
two stage design using the Gehan principle8. Initially 15 patients were recruited, then 
extended to 50 patients as responses were observed in at least 2 individuals. The study 
was further extended to 80 patients after discussion with the LREC. 
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Results  
Patient Characteristics  
A total of 80 patients were recruited over a 2 year period (from February 2002 to 
February 2004). Fifty eight received at least 2 cycles (8 weeks) of study medication and 
were included in the safety and intention-to-treat analysis (ITT). The median duration 
of treatment for these patients was 8 cycles. Eighteen patients received less than 8 
weeks of therapy and therefore were non-evaluable. This was due to patient choice 
(2/18 cases), rapidly progressive symptoms (7/18), rapid PSA rise (8/18) and rash 
(1/18). The remaining four patients were ineligible as they commenced other 
medication which may have affected the PSA value.  Mean age of the patients was 70 
years (range 51-86); 78 % of patients were Caucasian and 22% Afro-Caribbean. The 
WHO performance status was 0,1,2 in 16 (20%), 28 (35%) and  36 (45%) of the 
patients respectively, table 1. The median PSA was 43.9 and 168 for the evaluable and 
non-evaluable cohorts respectively. The mean combined Gleason grade was 7 (range 6-
9) in evaluable and 8 in non-evaluable (range 6-10) patients. Over half of the patients 
had localised recurrent disease characterised by a normal bone scan, absence of nodal 
or visceral metastases but with a rising PSA despite LHRH-containing hormonal 
therapy.  
 
Toxicity 
Toxicity information was collected for all patients. For each patient, the worst grades 
seen of the most common haematologic and non-haematologic toxicities are 
summarized in table 2. The treatment was generally well tolerated. Grade 2 fatigue 
symptoms were reported in five patients after 6 months, although all patients chose to 
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continue with the treatment. The study agent did not exacerbate urinary symptoms in 
any patient, nor was there evidence of haematuria on urine testing, even after prolonged 
administration. The most significant finding was grade 3 lymphopaenia, observed in 19 
(32.8%) patients. Lymphopaenia is not normally a limiting toxicity in studies involving 
chemotherapeutic agents. This persisted despite dose reducing or stopping the drug in 3 
patients, and necessitated prophylactic cover with oral co-trimoxazole for opportunistic 
infection, and conversion to a lower dose or alternative therapy. In total five patients 
had dose reductions to their therapy. No clinical or radiological indications of an 
opportunistic infection as a result of lymphopaenia were found at any time. Three 
patients required treatment breaks of over 2 weeks before re-commencing at 25% dose 
reduction due to neutropaenia, anaemia and diarrhoea. One patient developed a sputum 
culture-positive bacterial respiratory infection which responded promptly to 
amoxycillin. A further patient developed a typical allergic drug rash after the second 
day of treatment. Two patients developed non-painful cutaneous herpes zoster after 4 
and 6 months, which responded to zovirax and had no subsequent sequelae. No second 
malignancy has been reported in any study patient to date. 
 
Efficacy 
On an intention to treat basis, the response rate was 34.5% inclusive of objective and 
PSA (absolute reduction and reduction in PSAV) parameters, table 3. One patient had a 
partial response by RECIST, and two patients a PSA fall of >50%. The majority of the 
responders had localised disease, with no clear difference in patients with bone and/or 
nodal disease. There was no correlation between response and Gleason grading or 
ethnicity. The majority of the non responders had either locally advanced or bone 
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metastatic disease. The median duration of response was 7.5 months (confidence 
intervals 3-18 months), the median survival has not yet been reached. The overall 
survival is shown in figure 1. The proportion of patients still alive reflects the high 
proportion with localised disease at recruitment. There was no correlation between 
survival and Gleason grading or site of metastases. The majority of patients stopped 
treatment due to rapidly rising PSA, although a significant proportion included grade 3 
haematological toxicity (lymphopaenia mainly) or objective progression by radiology, 
table 4. Four patients continued with therapy beyond the first 12 cycles.  
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Discussion 
Despite the reported survival benefit with taxane-based chemotherapy, the prognosis for 
HRPC patients is still guarded. This study has shown that CY may be administered in a 
metronomic schedule and is capable of positively altering PSA kinetics without 
significant toxicity. The median duration of response to metronomic CY was at least 
that expected with second line hormonal agents but without the toxicity. The advantages 
of low dose CY were its convenient oral administration, low cost, dosing schedule and 
lack of toxicity.  
The patients enrolled to the study represented a typical cross section of this disease in 
the clinic- including patients with purely biochemical PSA failure up to those with more 
advanced and evaluable disease. The majority of patients had localised disease and 
rising PSA although significant numbers of patients with bone metastases were included. 
Our experience with immunological status of patients with nodal (or no) metastases 
versus bone metastases indicates the presence of bone disease is associated with 
profound immunosuppression (manuscript submitted). Patients who were unable to 
continue with the study to the 3 month time point so as to be non-evaluable were 
characterised by a higher mean PSA, more bone or bone/nodal disease and a slightly 
higher Gleason grade of 8.  
Treatment related toxicity was mild, with no CY-related serious adverse events and no 
symptoms to suggest haemorrhagic cystitis or second malignancies. Although 
lymphopaenia was observed in 19 patients, there were no clinical complications. 
Myelotoxicity has been reported with this dose of CY previously, and it is also possible 
that a significant proportion of men had disease metastatic to bone marrow and/or 
anaemia of chronic disease. 
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Although the number of responders was modest on conventional criteria, there have 
been a number of studies indicating the utility of PSA kinetics as response criteria. This 
has included reduction in PSA of less than 50% and reduction in PSA velocity 
(increased PSA doubling time)9. On the other hand, vaccine therapy for prostate cancer 
has been associated with increased survival without significant alterations in serum 
PSA10. In our recent evaluation of an allogeneic whole cell vaccine for HRPC patients, 
none of the 28 patients enrolled had objective or conventional PSA responses but a 
significant proportion had a fall in PSA velocity and an increased time to disease 
progression compared to other agents used for the same patient group11. In terms of the 
32 non-responders in this study, there were equal number of patients with bone involved 
and locally advanced tumours. There was no clear correlation with their histology, 
ethnicity or previous therapy. It is noteworthy that the main reason to stop treatment in 
these patients was related to disease progression as noted by an increase in PSA levels, 
worsening radiological or clinical symptoms and not due to toxicity of the agent. 
It is clear from murine and human studies that the biological effect of CY may depend 
on dose and delivery schedule. Higher doses are associated with cytotoxicity and 
immunosuppression, whereas continuous low dose scheduling may be 
immunostimulatory and/or antiangiogenic. Previous studies have reported significant 
stabilising effects of CY but modest if any response to moderate to high doses of bolus 
CY, although these studies are from the pre-PSA and pre-CT scan era12. Metronomic 
type dosing of CY has been previously reported as a single agent in one 5 patient 
study13 but otherwise has been used in combination with potentially immunosuppressive 
agents such as steroids and conventional doses of cytotoxic agents in prostate and other 
cancers.  We believe that the observed effects of CY were unlikely to be explained 
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purely by the cytotoxic actions of CY at this dose. Instead, the immunoregulatory and 
anti-angiogenic effects were probably more likely to explain the data. We assessed the 
effect of continuous CY on circulating T regs in 20 patients after 3 months following 
numerous reports of effects in murine models and found no clear correlation with any 
clinical, pathological or biochemical factors in the study (data not shown). A 
comparison after 3 months may have been insufficient time, and changes in the 
intratumoural rather than the circulating T regs may be more important to ascertain. 
Although the number of samples available for analysis was ultimately small, we did 
observe a reduction in expression of TGFβ by the T regs post- versus pre-treatment. The 
antiangiogenic effects of CY are well documented, with direct evidence of effect on 
microvessel sprouting14. PC is associated with a large number of angiogenic factors, and 
VEGF expression is increased in androgen-independent tumours15. Hamano et al. (2004) 
demonstrated that low-dose cyclophosphamide inhibits tumour growth by upregulating 
the endogenous angiogenesis inhibitor thrombospondin-1 in tumour and perivascular 
cells. Thrombospondin-1, in turn, promotes endothelial cell apoptosis16. CY may be 
acting as an antiangiogenic agent in this study by induction of potent antiangiogenic 
factors such as thromobospondin in tumour cells10. Although our assessment of VEGF 
expression was inconclusive, there are a number of newer assays which may be utilised 
in future studies. 
Conclusions 
In summary, we have shown that oral CY can be used on a continual basis safely in men 
with HRPC. Antitumour and marker responses were observed in patients with nodal and 
bone metastatic disease. The low toxicity, low cost, ease of administration, 
immunoregulatory and antiangiogenic potential of CY makes it a prime candidate for 
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combination with vaccines and other antiangiogenic agents. For the palliative effects 
shown in this study we intend to pursue a further study randomising metronomic CY 
against dethyl stilboestrol to include quality of life assessment. 
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Figure Legends 
 
Figure 1 – Overall survival of hormone resistant prostate cancer patients treated with  
low dose metronomic oral cyclophosphamide. 
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 Evaluable  Non-Evaluable   
  (n=58)  (n=18)   
Age, years         
Range 51-86   60-84   
Median 69   71   
       
Baseline PSA      
Range  2.4-789  19-1973   
Median 43.9  168   
       
Sites of Disease number % number % 
Localised 30 51.7 2 11.1 
Bone 20 34.5 11 61.1 
Nodal 4 6.9 2 11.1 
Bone & Nodal 4 6.9 3 16.6 
*Number of 
previous 
treatments 
    1 - 24 
    2  -21 
  3 - 9 
>3- 1  
1 - 2 
2 - 6 
3 - 8 
>3 - 2  
     
 
*where previous therapy not confirmed, omitted 
 
Table 1 Patient demographics. 
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Toxicity 
CTC 
Grade n % 
Lymphopenia 1 3 5.2 
  2 36 62 
  3 19 32.8 
Neutropenia 1 4 6.9 
  2 1 1.7 
  3 1 1.7 
Thrombocytopenia 1 5 8.6 
  2 3 5.2 
  3 0 0 
Anaemia 1 3 5.2 
  2 12 20.7 
  3 1 1.7 
Fatigue 1 5 8.6 
 2 5 8.6 
Nausea 1 1 1.7 
Renal impairment 1 1 1.7 
Diarrhoea 1 1 1.7 
Rash 1 1 1.7 
 
Table 2  Toxicity observed in all evaluable patients using NCI Common Toxicity 
Criteria. 
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     Sites of Disease (%)   
  n = 58   % Local Bone Nodal 
Bone & 
Nodal 
Responders 26 44.8 14 (54) 5 (19.2) 4 (15.4) 3 (11.5) 
Objective & PSA 
Responders 3 5.2 1 (33.3) 1 (33.3) 0 (0) 1 (33.3) 
PSA Responders 
(<50%) 10 17.2 6 (60) 2 (20) 1 (10) 1 (10) 
PSA Velocity 
Responders 13 22.4 7 (54) 2 (15.4) 3 (23) 1 (7.7) 
         
Non-Responders 32 55.2 16 (50) 15 (46.9) 0 (0) 1 (3.1) 
         
Total 58 100 30 20 4 4 
 
 
Table 3 Response to CY therapy and correlation to site of disease 
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Reason for Stopping 
Treatment n = 58 % 
Rising PSA 29 50 
Objective PD 9 15.5 
Progressive Symptoms 2 3.5 
Haematological Toxicity 13 22.4 
Duration of Therapy > 12 
months 4 6.9 
    
Treatment Ongoing 1 1.7 
 
Table 4 Treatment status of patients and reasons for stopping metronomic CY therapy 
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Figure 1 – Overall survival of hormone resistant prostate cancer patients treated with  
low dose metronomic oral cyclophosphamide. 
 
 
 
 
